Venous thromboembolism in hematopoietic stem cell transplant recipients

被引：24

作者：

Chaturvedi, S. ^{[1
,2
]}

Neff, A. ^{[3
]}

Nagler, A. ^{[4
]}

Savani, U. ^{[5
]}

Mohty, M. ^{[6
]}

Savani, B. N. ^{[1
,2
]}

机构：

[1] Vanderbilt Univ, Med Ctr, Dept Med, Hematol & Stem Cell Transplantat Sect,Div Hematol, 1301 Med Ctr Dr,3927 TVC, Nashville, TN 37232 USA

[2] Vet Affairs Med Ctr, 1301 Med Ctr Dr,3927 TVC, Nashville, TN 37232 USA

[3] Cleveland Clin, Dept Hematol Oncol & Blood Disorders, Benign Hematol Program, Cleveland, OH 44106 USA

[4] Chaim Sheba Med Ctr, Dept Med, Div Hematol, Tel Hahomer, Israel

[5] Univ Michigan, Ann Arbor, MI 48109 USA

[6] St Antoine Hosp, Dept Haematol, Paris, France

来源：

BONE MARROW TRANSPLANTATION | 2016年 / 51卷 / 04期

关键词：

BONE-MARROW-TRANSPLANTATION; CLINICAL-PRACTICE GUIDELINES; CATHETER-RELATED THROMBOSIS; DEEP-VEIN THROMBOSIS; UNSUSPECTED PULMONARY EMBOLI; REFRACTORY MULTIPLE-MYELOMA; HUMAN ENDOTHELIAL-CELLS; LOW-DOSE DEXAMETHASONE; ILL MEDICAL PATIENTS; VERSUS-HOST-DISEASE;

D O I：

10.1038/bmt.2015.308

中图分类号：

Q6 [生物物理学];

学科分类号：

071011 ;

摘要：

Venous thromboembolism (VTE) is an increasingly recognized problem in the post-hematopoietic stem cell transplantation (HSCT) setting, with a lack of high-quality evidence-based data to recommend best practices. Few patients with hematologic malignancies and even fewer post-HSCT patients were included in randomized trials of VTE prophylaxis and treatment. Prior VTE, GVHD, infections and indwelling venous catheters are risk factors for thrombosis. The increasing use of post-transplant maintenance therapy with lenalidomide in patients with multiple myeloma adds to this risk after autologous HSCT. These patients are also at high risk of bleeding complications because of prolonged thrombocytopenia and managing the competing risks of bleeding and thrombosis can be challenging. This review aims to provide a practical, clinician-focused approach to the prevention and treatment of VTE in the post-HSCT setting.

引用

页码：473 / 478

页数：6

共 80 条

[1] Prevalence of inherited prothrombotic abnormalities and central venous catheter-related thrombosis in haematopoietic stem cell transplants recipients [J].

Abdelkefi, A ;

Ben Romdhane, N ;

Kriaa, A ;

Chelli, M ;

Torjman, L ;

Ladeb, S ;

Ben Othman, T ;

Lakhal, A ;

Guermazi, S ;

Ben Hassen, A ;

Ladeb, F ;

Ben Abdeladhim, A .

BONE MARROW TRANSPLANTATION, 2005, 36 (10) :885-889

[2] Semuloparin for Thromboprophylaxis in Patients Receiving Chemotherapy for Cancer [J].

Agnelli, Giancarlo ;

George, Daniel J. ;

Kakkar, Ajay K. ;

Fisher, William ;

Lassen, Michael R. ;

Mismetti, Patrick ;

Mouret, Patrick ;

Chaudhari, Umesh ;

Lawson, Francesca ;

Turpie, Alexander G. G. .

NEW ENGLAND JOURNAL OF MEDICINE, 2012, 366 (07) :601-609

[3] Nadroparin for the prevention of thromboembolic events in ambulatory patients with metastatic or locally advanced solid cancer receiving chemotherapy: a randomised, placebo-controlled, double-blind study [J].

Agnelli, Giancarlo ;

Gussoni, Gualberto ;

Bianchini, Carlo ;

Verso, Melina ;

Mandala, Mario ;

Cavanna, Luigi ;

Barni, Sandra ;

Labianca, Roberto ;

Buzzi, Franco ;

Scambia, Giovanni ;

Passalacqua, Rodolfo ;

Ricci, Sergio ;

Gasparini, Giampietro ;

Lorusso, Vito ;

Bonizzoni, Erminio ;

Tonato, Maurizio .

LANCET ONCOLOGY, 2009, 10 (10) :943-949

[4] Anticoagulation for thrombosis prophylaxis in cancer patients with central venous catheters [J].

Akl, E. A. ;

Karmath, G. ;

Yosuico, V ;

Kim, S. Y. ;

Barba, M. ;

Sperati, F. ;

Cook, D. ;

Schuenemann, H. J. .

COCHRANE DATABASE OF SYSTEMATIC REVIEWS, 2007, (03)

[5] Risk factors for venous thromboembolism in hospitalized patients with acute medical illness - Analysis of the MEDENOX study [J].

Alikhan, R ;

Cohen, AT ;

Combe, S ;

Samama, MM ;

Desjardins, L ;

Eldor, A ;

Janbon, C ;

Leizorovicz, A ;

Olsson, CG ;

Turpie, AGG .

ARCHIVES OF INTERNAL MEDICINE, 2004, 164 (09) :963-968

[6] Risk factors for venous thromboembolism [J].

Anderson, FA ;

Spencer, FA .

CIRCULATION, 2003, 107 :I9-I16

[7]

[Anonymous], VEN THROMB DIS MAN V

[8] Extracorporeal photopheresis therapy in the management of steroid-refractory or steroid-dependent cutaneous chronic graft-versus-host disease after allogeneic stem cell transplantation:: feasibility and results [J].

Apisarnthanarax, N ;

Donato, M ;

Körbling, M ;

Couriel, D ;

Gajewski, J ;

Giralt, S ;

Khouri, I ;

Hosing, C ;

Champlin, R ;

Duvic, M ;

Anderlini, P .

BONE MARROW TRANSPLANTATION, 2003, 31 (06) :459-465

[9] Thalidomide and hematopoietic-cell transplantation for multiple myeloma [J].

Barlogie, B ;

Tricot, G ;

Anaissie, E ;

Shaughnessy, J ;

Rasmussen, E ;

van Rhee, F ;

Fassas, A ;

Zangari, M ;

Hollmig, K ;

Pineda-Roman, M ;

Lee, C ;

Talamo, G ;

Thertulien, R ;

Kiwan, E ;

Krishna, S ;

Fox, M ;

Crowley, J .

NEW ENGLAND JOURNAL OF MEDICINE, 2006, 354 (10) :1021-1030

[10] A prospective longitudinal multicenter study of coagulation in pediatric patients undergoing allogeneic stem cell transplantation [J].

Brandao, Leonardo R. ;

Kletzel, Morris ;

Boulad, Farid ;

Kurtzberg, Joanne ;

Maloney, Kelly ;

Fligman, Igal ;

Sison, Cristina P. ;

DiMichele, Donna .

PEDIATRIC BLOOD & CANCER, 2008, 50 (06) :1240-1246

← 1 2 3 4 5 6 7 8 →